|
|
|
| Analysis on surveillance results of adverse events following immunization in Ningbo City |
| ZHOU Shao-ying, MA Rui
|
| The Center for Disease Control and Prevention of Ningbo City,Ningbo,Zhejiang 315010,China |
|
|
|
|
Abstract Objective To analyze the occurrence characteristics of adverse events following immunization（AEFI）in Ningbo and to provide the basis for evaluating the safety of vaccine. Methods The AEFI case data from 2009 to 2016 were collected by the Chinese Adverse Events Following Immunization Information Management System and the Chinese Immunization Planning Information Management System. The descriptive analysis was used for AEFI reporting time,demographic characteristics,classification,outcome and vaccine distribution. Results From 2009 to 2016,5 036 AEFI cases were reported. The average incidence rate was 18.36 per 100 000. The most of the cases were reported from May to August,which accounted for 44.18%. The most of cases were occurred in the infant group（≤ 1 year old）,which accounted for 66.30%. The highest incidence rate was occurred in the age group of 6 years,which was 47.87 per 100 000. Among 5 036 cases of AEFI,4 946 cases were vaccine reaction,accounting for 98.21%. The most of symptoms were fever,swelling and indurations,accounting for 84.69%. There were 4 523 cases（89.81%）of AEFI occurred within two day after vaccination. The incidence rate of Non national immunization program vaccine （19.59 per 100 000） was higher than that of national immunization program vaccine （17.89 per 100 000）（P<0.05）. Except 151 unknown,96.86%（4 878/5 036）cases were improved and recovered. Three cases of sequelae were all coincidence event. Among the 4 cases of death,in addition to 1 case of systemic disseminated BCG infection,3 of the other cases were coincidental event. Conclusion AEFI cases occurred mainly in the infant group and occurred within two day after vaccination. In general,the safety of vaccines was satisfied.
|
|
Received: 22 September 2017
Revised: 21 November 2017
Published: 06 March 2018
|
|
|
|
|
|
[1] 中华人民共和国卫生部,国家食品药品监督管理总局. 全国疑似预防接种异常反应监测方案[S]. 2010.
[2] 王帆,黄美林,刘世科. 浙江省宁海县2009—2012年疑似预防接种异常反应监测分析[J]. 上海预防医学,2014,26(2):73-75.
[3] 张颖,史珊珊. 余姚市疑似预防接种异常反应监测分析[J]. 预防医学,2016,28(11):1144-1145.
[4] 武文娣,刘大卫,李克莉,等. 中国2012年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫,2014,20(1):1-12.
[5] 叶家楷,李克莉,许涤沙,等. 中国2013年疑似预防接种异常反应信息管理系统数据分析[J]. 中国疫苗和免疫,2015,21(2):121-131.
[6] 叶家楷,李克莉,许涤沙,等. 中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J]. 中国疫苗和免疫,2016,22(2):125-137.
[7] 叶家楷,李克莉,许涤沙,等. 中国2015年疑似预防接种异常反应监测分析[J]. 中国疫苗和免疫,2017,23(5):481-492.
[8] 潘雪娇,李倩,戚小华,等. 浙江省2013—2014年疑似预防接种异常反应监测数据分析[J]. 浙江预防医学,2015,27(11):1128-1130.
[9] 刘宇,赵占杰,谢莘,等. 广东省2005—2014年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫,2016,22(2):202-209.
[10] 常琳,韩悦,姚文清. 辽宁省2009—2013年疑似预防接种异常反应监测分析[J]. 中国疫苗和免疫,2015,21(2):132-138.
[11] 叶莹,史鲁斌,李军,等. 河南省2009至2014年疑似预防接种异常反应监测分析[J]. 郑州大学学报(医学版),2016,51(2):258-262.
[12] 凌罗亚,戚小华,李倩,等. 基于监测系统的浙江省2011年疑似预防接种异常反应发生情况研究[J]. 浙江预防医学,2013,25(6):26-32.
[13] 龚琼宇,陈玉娟,胡筱莛,等. 云南省2015年疑似预防接种异常反应监测分析[J]. 中国疫苗和免疫,2016,22(5):571-577.
[14] 凌罗亚,胡昱,陈恩富,等. 浙江省2010年麻疹-流行性腮腺炎联合减毒活疫苗强化免疫疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2011,17(4):357-361.
[15] 陈敏,丁筱竹. 2010—2013年南京市疑似预防接种异常反应监测分析[J]. 江苏预防医学,2015,26(1):25-27.
[16] 彭时辉,文海蓉,许波,等. 2009—2013 年南昌市疑似预防接种异常反应监测分析[J]. 现代预防医学,2015,42(3):537-539.
[17] 陈佳婧,应颖,蒋丽丽. 2009—2015年上海市普陀区疑似预防接种异常反应监测结果分析[J]. 现代预防医学,2017,44(1):174-176.
[18] 徐若辉,蔡润,富继业,等. 北京市海淀区 2008—2013 年疑似预防接种异常反应监测分析[J]. 中国生物制品学杂志,2015, 28(6):618-622.
[19] 陈红丹,林献丹,刘丽琳,等. 疑似预防接种异常反应监测评价[J]. 浙江预防医学,2015,27(5):480-482. |
|
|
|
